Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses

Neuroendocrinology Letters

Volumn 32, Issue 4, 2011, Pages 428-436

  Melkersson, Kristina ^a   Berinder, Katarina ^a   Hulting, Anna Lena ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic drug; Blood lipids; Body mass index; Insulin sensitivity; Prolactin; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CLOZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; ORPHENADRINE; RISPERIDONE; ZOLPIDEM; ZOPICLONE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERPROLACTINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80053502161     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen R (2003) Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry. 160: 1618-1620. (Pubitemid 41079547)
2. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem. 20: 470-475.
3. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al (1999) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 60: 215-220. (Pubitemid 29193917)
4. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC, USA: American Psychiatric Press.
5. Ataya K, Mercado A, Kartaginer J, Abbasi A, Moghissi KS (1988) Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril. 50: 876-881. (Pubitemid 19017956)
6. Bang P, Eriksson U, Sara V, Wivall I-L, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol. 124: 620-629.
7. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 64: 761-766. (Pubitemid 36897211)
8. Beck-Nielsen H, Hother-Nielsen O (2000) Obesity in type 2 diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus. A fundamental and clinical text, 2nd ed. Philadelphia, USA: Lippincott Williams & Wilkins. p. 567.
9. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone [review]. Trends Endocrinol Metab. 17: 110-116.
10. Berinder K, Nyström T, Höybye C, Hall K, Hulting A-L (2010) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. doi 10.1007/s11102-010-0277-9.
11. Beumont PJV, Gelder MG, Friesen HG, Harris GW, MacKinnon PCB, Mandelbrote BM, et al (1974) The effects of phenothiazines on endocrine function: I Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry. 124: 413-419.
12. Brown S (1997) Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 171: 502-508.
13. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 85: 295-305.
14. Cole TG, Ferguson CA, Gibson DW, Nowatzke WL (2001) Optimization of β-quantification methods for high-throughput applications. Clin Chem. 47: 712-721. (Pubitemid 32275815)
15. Dahlöf B (2010) Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 105(suppl): 3A-9A.
16. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O (2010) Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol. 73: 502-507.
17. Esel E, Basturk M, Gonul AS, Kula M, Turan T, Yabanoglu I, et al (2001) Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology. 26: 641-647. (Pubitemid 32524192)
18. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18: 499-502.
19. Ghadirian AM, Chouinard G, Annable L (1982) Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 170: 463-467. (Pubitemid 12051650)
20. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the Catie study and matched controls. Schizophr Res. 80: 45-53. (Pubitemid 41587462)
21. Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol. 48: 547-553. (Pubitemid 28252990)
22. Haffner SM, Miettinen H, Stern MP (1997) The homeostasis model in the San Antonio heart study. Diabetes Care. 20: 1087-1092. (Pubitemid 27274268)
23. Hilding A, Hall K, Wivall-Helleryd I-L, Sääf M, Melin A-L, Thoren M (1999) Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab. 84: 2013-2019. (Pubitemid 30647027)
24. Huang M-L, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, et al (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 54: 257-268. (Pubitemid 23294526)
25. Inoue H, Hazama H, Ogura C, Ichikawa M, Tamura T (1980) Neuroendocrinological study of amenorrhea induced by antipsychotic drugs. Folia Psych Neurol. 34: 181. (Pubitemid 10017365)
26. Johnston DG, Alberti KGMM, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K, et al (1980) Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol. 13: 361-368. (Pubitemid 10004303)
27. Keely EJ, Reiss JP, Drinkwater DT, Faiman C (1997) Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr Pract. 3: 209-213.
28. Kelly C, McCreadie RG (1999) Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry. 156: 1751-1757. (Pubitemid 29517568)
29. Kinon BJ, Gilmore JA, Liu H, Halbreich UM (2003) Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 28: 55-68. (Pubitemid 36332229)
30. Labhart A (1986) Classification of diabetes mellitus. In: Thorn GW, Assal JP, editors. Clinical Endocrinology: Theory and Practice. Berlin, Germany: Springer-Verlag. p. 775-777.
31. Landgraf R, Landgraf-Leurs MMC, Weissmann A, Hörl R, Von Werder K, Scriba PC (1977) Prolactin: a diabetogenic hormone. Diabetologia. 13: 99-104. (Pubitemid 8077629)
32. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI (1985) Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 41: 810-817. (Pubitemid 15092891)
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419. (Pubitemid 15018832)
34. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 184: 503-508. (Pubitemid 38725710)
35. Melkersson K (2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 66: 761-767.
36. Melkersson K (2009) Familial and sporadic schizophrenia: a comparison of somatic diseases and abuse in patients and their relatives. Acta Neuropsychiatr. 21: 4-10.
37. Melkersson KI, Hulting A-L, Brismar K (1999) Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 60: 783-791.
38. Melkersson KI, Hulting A-L, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 61: 742-749.
39. Melkersson KI, Hulting A-L, Rane AJ (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 51: 317-324. (Pubitemid 32391486)
40. Mukherjee S, Decina P, Boccola V, Saraceni F, Scapicchio PL (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 37: 68-73. (Pubitemid 26024880)
41. Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol. 16: 383-390. (Pubitemid 12188630)
42. Reichlin S (1998) Neuroendocrinology. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Textbook of Endocrinology, 9th ed. Philadelphia, PA, USA: W.B. Saunders Company. p. 192-197.
43. Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia. 28: 138-142. (Pubitemid 15102183)
44. Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 136: 254-258.
45. Serri O, Li L, Mamputu J-C, Beauchamp M-C, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol. 64: 366-370.
46. Siegel S, Castellan NJ (1988) Multiple comparisons between treatments. In: Nonparametric Statistics for the Behavioral Sciences, 2nd ed. New York, NY, USA: McGraw-Hill Book Company. p. 213-214.
47. Smith RC, Lindenmayer J-P, Davis JM, Kelly E, Viviano TF, Cornwell J, et al (2009) Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry. 70: 1501-1513.
48. Spayd RW, Bruschi B, Burdick BA, Dappen GM, Eikenberry JN, Esders TW, et al (1978) Multilayer film elements for clinical analysis: applications to representative chemical determinations. Clin Chem. 24: 1343-1350. (Pubitemid 8392014)
49. Svestka J, Synek O, Tomanova J, Rodakova I, Cejpkova A (2007) Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuroendocrinol Lett. 28: 881-888.
50. Thorner MO, Vance ML, Laws ER, Horvath E, Kovacs K (1998) The anterior pituitary. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Textbook of Endocrinology, 9th ed. Philadelphia, PA, USA: W.B. Saunders Company. p. 249-340.
51. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 26: 341-346. (Pubitemid 36763695)
52. Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S (2009) Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary. 12: 330-334.
53. Urban A, Masopust J, Maly R, Hosak L, Kalnicka D (2007) Prolactin as a factor for increased platelet aggregation [review]. Neuroendocrinol Lett. 28: 518-523. (Pubitemid 47577736)
54. Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Hentschel B, Gertz HJ, et al (2003) Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol. 23: 479-483. (Pubitemid 37128676)
55. Weizman A, Maoz B, Treves I, Asher I, Ben-David M (1985) Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. Prog Neuro-Psychopharmacol & Biol Psychiatry. 9: 193-198. (Pubitemid 15089228)
56. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 64: 663-667.
57. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin Ö, et al (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 149: 187-193. (Pubitemid 37120990)